- NEWS AND VIEWS
The path to destruction for D-type cyclin proteins
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature 592, 690-691 (2021)
doi: https://doi.org/10.1038/d41586-021-00889-0
References
Simoneschi, D. et al. Nature 592, 789–793 (2021).
Chaikovsky, A. C. et al. Nature 592, 794–798 (2021).
Maiani, E. et al. Nature 592, 799–804 (2021).
Otto, T. & Sicinski, P. Nature Rev. Cancer 17, 93–115 (2017).
Sherr, C. J., Beach, D. & Shapiro, G. I. Cancer Discov. 6, 353–367 (2016).
Lin, D. I. et al. Mol. Cell 24, 355–366 (2006).
Chen, S.-H. et al. EMBO J. 37, e97508 (2018).
Petroski, M. D. & Deshaies, R. J. Nature Rev. Mol. Cell Biol. 6, 9–20 (2005).
Qie, S. & Diehl, J. A. J. Mol. Med. 94, 1313–1326 (2016).
Kanie, T. et al. Mol. Cell Biol. 32, 590–605 (2012).
Cianfanelli, V., Nazio, F. & Cecconi, F. Mol. Cell Oncol. 2, e970059 (2015).
Fimia, G. M. et al. Nature 447, 1121–1125 (2007).
Jin, J., Arias, E. E., Chen, J., Harper, J. W. & Walter, J. C. Mol. Cell 23, 709–721 (2006).
Cianfanelli, V. et al. Nature Cell Biol. 17, 20–30 (2015).
Bretones, G., Delgado, M. D. & Leon, J. Biochim. Biophys. Acta 1849, 506–516 (2015).
Finn, R. S. et al. Lancet Oncol. 16, 25–35 (2015).
Finn, R. S. et al. Clin. Cancer Res. 26, 110–121 (2020).
Li, Z. et al. Cancer Cell 34, 893–905 (2018).
Turner, N. C. et al. J. Clin. Oncol. 37, 1169–1178 (2019).
Herrera-Abreu, M. T. et al. Cancer Res. 76, 2301–2313 (2016).
Competing Interests
P.S. has been a consultant at Novartis, Genovis, Guidepoint, The Planning Shop, ORIC Pharmaceuticals, Syros, Cedilla Therapeutics and Exo Therapeutics. His laboratory has received research funding from Novartis.